David Scherer, Steffen Honrath, Jonas Kurmann, Alexander Klipp, Finn Brigger, Jean-Christophe Leroux
{"title":"Comparison of Receptor-Mediated Endocytosis and Its Application to Enhance DNA Transfection by TFAMoplex","authors":"David Scherer, Steffen Honrath, Jonas Kurmann, Alexander Klipp, Finn Brigger, Jean-Christophe Leroux","doi":"10.1002/anbr.70124","DOIUrl":null,"url":null,"abstract":"<p>Receptor-targeting ligands can improve the specificity and cellular uptake of drugs and gene delivery systems. However, there is currently a lack of rapid, high-throughput assays to identify ligands that efficiently induce endocytosis. To address this gap, we developed a flow cytometric assay that selectively quantifies internalized fluorescence, directly converting endosomal uptake into an easily measurable signal across entire cell populations and avoiding the ambiguity and labor intensity of microscopy-based methods. Using this platform, we identified ligands that induce cellular uptake and applied them to the TFAMoplex, a modular, protein-based nonviral gene delivery system recently developed in our group. Coupling of heparin-binding epidermal growth factor, identified as an efficient internalizing ligand with the endocytosis assay, enhanced TFAMoplex uptake and transfection efficacy. These results support a generalizable strategy to rapidly screen uptake ligands, enabling the rational design of improved nonviral gene delivery systems.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 8","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.70124","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.70124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Receptor-targeting ligands can improve the specificity and cellular uptake of drugs and gene delivery systems. However, there is currently a lack of rapid, high-throughput assays to identify ligands that efficiently induce endocytosis. To address this gap, we developed a flow cytometric assay that selectively quantifies internalized fluorescence, directly converting endosomal uptake into an easily measurable signal across entire cell populations and avoiding the ambiguity and labor intensity of microscopy-based methods. Using this platform, we identified ligands that induce cellular uptake and applied them to the TFAMoplex, a modular, protein-based nonviral gene delivery system recently developed in our group. Coupling of heparin-binding epidermal growth factor, identified as an efficient internalizing ligand with the endocytosis assay, enhanced TFAMoplex uptake and transfection efficacy. These results support a generalizable strategy to rapidly screen uptake ligands, enabling the rational design of improved nonviral gene delivery systems.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.